Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Breast Cancer

  Free Subscription

Articles published in Breast Cancer

Retrieve available abstracts of 228 articles:
HTML format

Single Articles

    September 2023
  1. PATIL PB, Patel JK
    Preparation, characterization, and in vitro cytotoxicity activity of allyl-isothiocyanate-embedded polymeric nanoparticles for potential breast cancer targeting.
    Breast Cancer. 2023 Sep 11. doi: 10.1007/s12282-023-01501.
    PubMed     Abstract available

  2. VIDULA N, Yau C, Rugo HS
    Glutaminase (GLS1) gene expression in primary breast cancer.
    Breast Cancer. 2023 Sep 7. doi: 10.1007/s12282-023-01502.
    PubMed     Abstract available

  3. VOLLBACH FH, Neuss C, Siegwart LC, Bigdeli AK, et al
    The transverse myocutaneous gracilis flap (TMG) for breast reconstruction: ipsi vs. contralateral harvest-aesthetic outcome and refinement procedures.
    Breast Cancer. 2023;30:845-855.
    PubMed     Abstract available

  4. GHILLI M, Mariniello MD, Ferre F, Morganti R, et al
    Quality of life and satisfaction of patients after oncoplastic or traditional breast-conserving surgery using the BREAST-Q (BCT module): a prospective study.
    Breast Cancer. 2023;30:802-809.
    PubMed     Abstract available

  5. TAKEHARA Y, Matsuda N, Kobayashi D, Yoshida A, et al
    Radiation-induced angiosarcoma of the breast: individual participant meta-analysis of Japanese population.
    Breast Cancer. 2023;30:739-747.
    PubMed     Abstract available

  6. FUKUI R, Watanabe T, Morimoto K, Fujimoto Y, et al
    An increase in tumor-infiltrating lymphocytes after treatment is significantly associated with a poor response to neoadjuvant endocrine therapy for estrogen receptor-positive/HER2-negative breast cancers.
    Breast Cancer. 2023;30:703-713.
    PubMed     Abstract available

    August 2023
  7. DONG H, Yang C, Chen X, Sun H, et al
    Breast cancer-derived exosomal lncRNA SNHG14 induces normal fibroblast activation to cancer-associated fibroblasts via the EBF1/FAM171A1 axis.
    Breast Cancer. 2023 Aug 31. doi: 10.1007/s12282-023-01496.
    PubMed     Abstract available

  8. SANUKI F, Mikami Y, Nishimura H, Fujita Y, et al
    Immunohistological analysis of B7-H4, IDO1, and PD-L1 expression and tumor immune microenvironment based on triple-negative breast cancer subtypes.
    Breast Cancer. 2023 Aug 29. doi: 10.1007/s12282-023-01498.
    PubMed     Abstract available

  9. MURATA T, Yoshida M, Shiino S, Watase C, et al
    Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer.
    Breast Cancer. 2023 Aug 23. doi: 10.1007/s12282-023-01500.
    PubMed     Abstract available

  10. OHSUMI S
    Reply to "Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?".
    Breast Cancer. 2023 Aug 21. doi: 10.1007/s12282-023-01495.

  11. OEI SL, Thronicke A, Grieb G, Schad F, et al
    Evaluation of quality of life in breast cancer patients who underwent breast-conserving surgery or mastectomy using real-world data.
    Breast Cancer. 2023 Aug 16. doi: 10.1007/s12282-023-01494.
    PubMed     Abstract available

  12. JHANGIANI N, Philip M, Jatoi I
    Breast cancer screening guidelines: discrepancies raise concerns about validity.
    Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01493.

  13. AKSHAYA RL, Saranya I, Selvamurugan N
    MicroRNAs mediated interaction of tumor microenvironment cells with breast cancer cells during bone metastasis.
    Breast Cancer. 2023 Aug 14. doi: 10.1007/s12282-023-01491.
    PubMed     Abstract available

  14. ILIE SM, Briot N, Constantin G, Roussot N, et al
    Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy.
    Breast Cancer. 2023 Aug 10. doi: 10.1007/s12282-023-01490.
    PubMed     Abstract available

    July 2023
  15. CHEN ST, Lai HW, Chang JH, Liao CY, et al
    Diagnostic accuracy of pre-operative breast magnetic resonance imaging (MRI) in predicting axillary lymph node metastasis: variations in intrinsic subtypes, and strategy to improve negative predictive value-an analysis of 2473 invasive breast cancer p
    Breast Cancer. 2023 Jul 27. doi: 10.1007/s12282-023-01488.
    PubMed     Abstract available

  16. KAWAMURA C, Iwagami M, Sun Y, Komiyama J, et al
    Factors associated with non-participation in breast cancer screening: analysis of the 2016 and 2019 comprehensive survey of living conditions in Japan.
    Breast Cancer. 2023 Jul 25. doi: 10.1007/s12282-023-01486.
    PubMed     Abstract available

  17. FUTAMURA M, Nakayama T, Yoshinami T, Oshiro C, et al
    Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316).
    Breast Cancer. 2023 Jul 24. doi: 10.1007/s12282-023-01485.
    PubMed     Abstract available

  18. JESUS OJ, Luis CP, Matilde MF
    Effects of exercise on cancer-related cognitive impairment in breast cancer survivors: a scoping review.
    Breast Cancer. 2023 Jul 22. doi: 10.1007/s12282-023-01484.
    PubMed     Abstract available

  19. LI C, Yuan Q, Deng T, Xu G, et al
    Prognosis difference between HER2-low and HER2-zero breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2023 Jul 20. doi: 10.1007/s12282-023-01487.
    PubMed     Abstract available

  20. JIANG T, Chen J, Wang Z, Wang X, et al
    miR-4796 enhances the sensitivity of breast cancer cells to ionising radiation by impairing the DNA repair pathway.
    Breast Cancer. 2023 Jul 17. doi: 10.1007/s12282-023-01482.
    PubMed     Abstract available

  21. MORIKAWA H, Oba T, Kiyosawa N, Iji R, et al
    Significance of skeletal muscle index-to-body mass index ratio as a predictor of post-surgical bleeding after mastectomy in patients with breast cancer.
    Breast Cancer. 2023 Jul 13. doi: 10.1007/s12282-023-01483.
    PubMed     Abstract available

  22. SUZUKI Y, Iwamoto T, Uno M, Hatono M, et al
    Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
    Breast Cancer. 2023 Jul 8. doi: 10.1007/s12282-023-01480.
    PubMed     Abstract available

  23. SAEKI S, Iwatani T, Kitano A, Sakurai N, et al
    Correction: Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
    Breast Cancer. 2023 Jul 3. doi: 10.1007/s12282-023-01479.

  24. LI L, Yang W, Jia D, Zheng S, et al
    Establishment of a N1-methyladenosine-related risk signature for breast carcinoma by bioinformatics analysis and experimental validation.
    Breast Cancer. 2023;30:666-684.
    PubMed     Abstract available

  25. WATANABE J, Kataoka Y, Koike A, Miki A, et al
    Efficacy and safety of surgical energy devices for axillary node dissection: a systematic review and network meta-analysis.
    Breast Cancer. 2023;30:531-540.
    PubMed     Abstract available

  26. KAWAGUCHI S, Kinowaki K, Tamura N, Masumoto T, et al
    High-accuracy prediction of axillary lymph node metastasis in invasive lobular carcinoma using focal cortical thickening on magnetic resonance imaging.
    Breast Cancer. 2023;30:637-646.
    PubMed     Abstract available

  27. MARINIELLO MD, Ghilli M, Favati B, Gerges I, et al
    Cell-free biomimetic polyurethane-based scaffold for breast reconstruction following non-malignant lesion resection. A first-in-human study.
    Breast Cancer. 2023;30:559-569.
    PubMed     Abstract available

  28. OIWA M, Suda N, Morita T, Takahashi Y, et al
    Validity of computed mean compressed fibroglandular tissue thickness and breast composition for stratification of masking risk in Japanese women.
    Breast Cancer. 2023;30:541-551.
    PubMed     Abstract available

  29. KIKUCHI M, Gomi N, Ueki A, Osako T, et al
    Effectiveness and tasks of breast MRI surveillance for high-risk women with cancer susceptibility genes other than BRCA1/2: a single institution study.
    Breast Cancer. 2023;30:577-583.
    PubMed     Abstract available

  30. FERNANDO H, Noelia G, Maria E, Pedro M, et al
    Centrally located breast carcinomas treated with central quadrantectomy and immediate nipple-areola reconstruction: a cohort study.
    Breast Cancer. 2023;30:552-558.
    PubMed     Abstract available

    June 2023
  31. KUTHETHUR R, Jerome MS, Subbannayya Y, Chakrabarty S, et al
    An integrated analysis of microRNAs regulating DNA damage response in triple-negative breast cancer.
    Breast Cancer. 2023 Jun 21. doi: 10.1007/s12282-023-01477.
    PubMed     Abstract available

  32. YIN M, Gu K, Cai H, Shu XO, et al
    Association between chronic pain and quality of life in long-term breast cancer survivors: a prospective analysis.
    Breast Cancer. 2023 Jun 17. doi: 10.1007/s12282-023-01472.
    PubMed     Abstract available

  33. RAINONE M, Behrendt CE, Kasparian S, Nguyen T, et al
    HER2-targeted antibody-drug conjugates for breast cancer: ancestry and dose adjustment for thrombocytopenia.
    Breast Cancer. 2023 Jun 16. doi: 10.1007/s12282-023-01473.
    PubMed     Abstract available

  34. SAEKI S, Iwatani T, Kitano A, Sakurai N, et al
    Factors associated with financial toxicity in patients with breast cancer in Japan: a comparison of patient and physician perspectives.
    Breast Cancer. 2023 Jun 13. doi: 10.1007/s12282-023-01476.
    PubMed     Abstract available

  35. YUSOF KM, Mohd Sidik S, Mahmud R, Abdullah M, et al
    Association of psychological distress with arm morbidity symptoms in breast cancer survivors: outcomes from the use of PHQ-9 and GAD-7 questionnaires.
    Breast Cancer. 2023 Jun 12. doi: 10.1007/s12282-023-01475.
    PubMed     Abstract available

  36. VAN BEKKUM S, Clarijs ME, van der Veen FJC, van Rosmalen J, et al
    What affects women's decision-making on breast reconstruction after mastectomy for breast cancer?
    Breast Cancer. 2023 Jun 12. doi: 10.1007/s12282-023-01471.
    PubMed     Abstract available

    May 2023
  37. ABDOLLAHI E, Mozdarani H, Alizadeh BZ
    Role of circ-FOXO3 and miR-23a in radiosensitivity of breast cancer.
    Breast Cancer. 2023 May 24. doi: 10.1007/s12282-023-01463.
    PubMed     Abstract available

  38. NOZAWA K, Terada M, Onishi M, Ozaki Y, et al
    Real-world treatment patterns and outcomes of abemaciclib for the treatment of HR + , HER2- metastatic breast cancer patients in Japan.
    Breast Cancer. 2023 May 22. doi: 10.1007/s12282-023-01461.
    PubMed     Abstract available

  39. LIN L, Pfender K, Ditsch N, Kuhn C, et al
    KLF11 is an independent negative prognostic factor for breast cancer from a cohort study and induces proliferation and inhibits apoptosis in vitro.
    Breast Cancer. 2023 May 18. doi: 10.1007/s12282-023-01470.
    PubMed     Abstract available

  40. KHALID F, Takagi K, Sato A, Yamaguchi M, et al
    Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration.
    Breast Cancer. 2023 May 13. doi: 10.1007/s12282-023-01467.
    PubMed     Abstract available

  41. YAMAUCHI H, Toi M, Takayama S, Nakamura S, et al
    Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 May 12. doi: 10.1007/s12282-023-01468.

  42. SAKAMOTO T, Tanimoto K, Eguchi H, Sasaki S, et al
    Resveratrol exhibits diverse anti-cancer activities through epigenetic regulation of E-cadherin and p21 in triple-negative breast cancer cells.
    Breast Cancer. 2023 May 11. doi: 10.1007/s12282-023-01465.
    PubMed     Abstract available

    Is there any association between acute kidney injury and olaparib use in patients with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 May 11. doi: 10.1007/s12282-023-01469.

    Is venous thromboembolism a time-dependent event in breast cancer patients taking tamoxifen?
    Breast Cancer. 2023 May 4. doi: 10.1007/s12282-023-01464.

  45. PATHAK R, Leslie M, Dondapati P, Davis R, et al
    Increased breast cancer mortality due to treatment delay and needle biopsy type: a retrospective analysis of SEER-medicare.
    Breast Cancer. 2023 May 3. doi: 10.1007/s12282-023-01456.
    PubMed     Abstract available

  46. LI JJ, Yu Y, Ge J
    HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC.
    Breast Cancer. 2023;30:364-378.
    PubMed     Abstract available

    April 2023
  47. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Correction: Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01454.

  48. JIAO Y, Guo X, Lv Q
    Options of locoregional therapy for primary foci of breast cancer influence the rate of nonregional lymph node metastasis in N2-N3 status patients: a SEER database analysis.
    Breast Cancer. 2023 Apr 27. doi: 10.1007/s12282-023-01459.
    PubMed     Abstract available

  49. OHSUMI S, Watanabe K, Kondo N, Kosaka Y, et al
    Venous thromboembolism in Japanese patients with breast cancer: subgroup analysis of the Cancer-VTE Registry.
    Breast Cancer. 2023 Apr 17. doi: 10.1007/s12282-023-01452.
    PubMed     Abstract available

  50. NOMURA T, Kawai M, Fukuma Y, Koike Y, et al
    Alcohol consumption and breast cancer prognosis after breast cancer diagnosis: a systematic review and meta‑analysis of the Japanese Breast Cancer Society Clinical Practice Guideline, 2022 edition.
    Breast Cancer. 2023 Apr 8. doi: 10.1007/s12282-023-01455.
    PubMed     Abstract available

  51. YAMAUCHI H, Toi M, Takayama S, Nakamura S, et al
    Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial.
    Breast Cancer. 2023 Apr 1. doi: 10.1007/s12282-023-01451.
    PubMed     Abstract available

    March 2023
  52. TAMURA K, Mukohara T, Yonemori K, Kawabata Y, et al
    Phase 1 study of oral selective estrogen receptor degrader (SERD) amcenestrant (SAR439859), in Japanese women with ER-positive and HER2-negative advanced breast cancer (AMEERA-2).
    Breast Cancer. 2023 Mar 29. doi: 10.1007/s12282-023-01443.
    PubMed     Abstract available

  53. AKYOL M, Tugral A, Aribas Z, Bakar Y, et al
    Assessment of the cardiorespiratory fitness and the quality of life of patients with breast cancer undergoing chemotherapy: a prospective study.
    Breast Cancer. 2023 Mar 23. doi: 10.1007/s12282-023-01453.
    PubMed     Abstract available

  54. SOWA Y, Inafuku N, Tsuge I, Yamanaka H, et al
    Development and implementation of a decision aid for post-mastectomy breast reconstruction for Japanese women with breast cancer: a field-testing study.
    Breast Cancer. 2023 Mar 18. doi: 10.1007/s12282-023-01447.
    PubMed     Abstract available

  55. NAGAHASHI M, Ling Y, Toshikawa C, Hayashida T, et al
    Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients.
    Breast Cancer. 2023 Mar 17. doi: 10.1007/s12282-023-01449.
    PubMed     Abstract available

  56. JINBO K, Fujita T, Kasahara R, Jinbo R, et al
    The effect of combined risk factors on breast cancer-related lymphedema: a study using decision trees.
    Breast Cancer. 2023 Mar 14. doi: 10.1007/s12282-023-01450.
    PubMed     Abstract available

  57. TOMIOKA N, Hatanaka KC, Okuyama D, Watanabe KI, et al
    Programmed death ligand 1-positive immune cells in primary tumor or metastatic axillary lymph nodes can predict prognosis of triple-negative breast cancer even when present at < 1% in the tumor region.
    Breast Cancer. 2023 Mar 9. doi: 10.1007/s12282-023-01442.
    PubMed     Abstract available

  58. SONG C, Kendi AT, Shim JY, Jung D, et al
    ER-/PR+ breast cancer is controlled more effectively with an inflammatory inhibitor than hormonal inhibitor.
    Breast Cancer. 2023 Mar 1. doi: 10.1007/s12282-023-01437.
    PubMed     Abstract available

  59. WANG F, Fang L, Fu B, Fan C, et al
    Construction of a prognostic risk assessment model for HER2 + breast cancer based on autophagy-related genes.
    Breast Cancer. 2023 Mar 1. doi: 10.1007/s12282-023-01440.
    PubMed     Abstract available

  60. YAMAKADO R, Ishitobi M, Kondo N, Yamauchi C, et al
    Physicians' perception about the impact of breast reconstruction on patient prognosis: a survey in Japan.
    Breast Cancer. 2023;30:302-308.
    PubMed     Abstract available

  61. KWON MR, Chang Y, Park B, Ryu S, et al
    Performance analysis of screening mammography in Asian women under 40 years.
    Breast Cancer. 2023;30:241-248.
    PubMed     Abstract available

  62. KONARA MUDIYANSELAGE SP, Wu YL, Kukreti S, Chen CC, et al
    Dynamic changes in quality of life, psychological status, and body image in women who underwent a mastectomy as compared with breast reconstruction: an 8-year follow up.
    Breast Cancer. 2023;30:226-240.
    PubMed     Abstract available

    February 2023
  63. ZHANG H, Barner JC, Moczygemba LR, Rascati KL, et al
    Comparing survival outcomes between neoadjuvant and adjuvant chemotherapy within breast cancer subtypes and stages among older women: a SEER-Medicare analysis.
    Breast Cancer. 2023 Feb 26. doi: 10.1007/s12282-023-01441.
    PubMed     Abstract available

  64. KOU K, Cameron J, Youl P, Pyke C, et al
    Severity and risk factors of interval breast cancer in Queensland, Australia: a population-based study.
    Breast Cancer. 2023 Feb 21. doi: 10.1007/s12282-023-01439.
    PubMed     Abstract available

  65. JIANG F, Yang L, Jiao X
    Dynamic network biomarker to determine the critical point of breast cancer stage progression.
    Breast Cancer. 2023 Feb 18. doi: 10.1007/s12282-023-01438.
    PubMed     Abstract available

  66. QING X, Yuan C, Wang K
    Characterization of protein-based risk signature to predict prognosis and evaluate the tumor immune environment in breast cancer.
    Breast Cancer. 2023 Feb 2. doi: 10.1007/s12282-023-01435.
    PubMed     Abstract available

    January 2023
  67. KADA MOHAMMED S, Billa O, Ladoire S, Jankowski C, et al
    HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
    Breast Cancer. 2023 Jan 30. doi: 10.1007/s12282-022-01432.
    PubMed     Abstract available

  68. IMOTO S, Wang K, Bi XW, Liu G, et al
    Survival advantage of locoregional and systemic therapy in oligometastatic breast cancer: an international retrospective cohort study (OLIGO-BC1).
    Breast Cancer. 2023 Jan 23. doi: 10.1007/s12282-023-01436.
    PubMed     Abstract available

  69. LI Y, Na F, Pei J
    Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification.
    Breast Cancer. 2023 Jan 20. doi: 10.1007/s12282-023-01434.
    PubMed     Abstract available

  70. COLLET L, Eberst L, Ludovic G, Debled M, et al
    Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
    Breast Cancer. 2023 Jan 11. doi: 10.1007/s12282-022-01427.
    PubMed     Abstract available

  71. HASAN MT, Hamouda M, Khashab MKE, Elsnhory AB, et al
    Oncoplastic versus conventional breast-conserving surgery in breast cancer: a pooled analysis of 6941 female patients.
    Breast Cancer. 2023 Jan 9. doi: 10.1007/s12282-022-01430.
    PubMed     Abstract available

  72. MA J, Wang F, Chen C, Ji J, et al
    Identification of prognostic genes signature and construction of ceRNA network in pirarubicin treatment of triple-negative breast cancer.
    Breast Cancer. 2023 Jan 9. doi: 10.1007/s12282-023-01433.
    PubMed     Abstract available

  73. FUTAMURA M, Ishihara K, Nagao Y, Ogiso A, et al
    Neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel plus trastuzumab and pertuzumab followed by epirubicin and cyclophosphamide for operable HER2-positive primary breast cancer: a multicenter phase II clinical trial (PerSeUS-BC04).
    Breast Cancer. 2023 Jan 7. doi: 10.1007/s12282-022-01425.
    PubMed     Abstract available

  74. BAILLEUX C, Arnaud A, Frenel JS, Chabaud S, et al
    CHEOPS trial: a GINECO group randomized phase II assessing addition of a non-steroidal aromatase inhibitor to oral vinorelbine in pre-treated metastatic breast cancer patients.
    Breast Cancer. 2023 Jan 5. doi: 10.1007/s12282-022-01426.
    PubMed     Abstract available

  75. OCHI T, Yoshida A, Takahashi O, Kajiura Y, et al
    Prognostic effect of subsequent childbirth after the diagnosis of breast cancer using propensity score matching analysis.
    Breast Cancer. 2023 Jan 3. doi: 10.1007/s12282-022-01429.
    PubMed     Abstract available

  76. OHSUMI S, Nishimura R, Masuda N, Akashi-Tanaka S, et al
    A prospective analysis of two studies that used the 5-mm interval slices and 5-mm margin-free method for ipsilateral breast tumor recurrence after breast-conserving surgery without radiotherapy.
    Breast Cancer. 2023;30:131-138.
    PubMed     Abstract available

  77. OHNEDA K, Hamanaka Y, Kawame H, Fuse N, et al
    Returning individual genomic results to population-based cohort study participants with BRCA1/2 pathogenic variants.
    Breast Cancer. 2023;30:110-120.
    PubMed     Abstract available

  78. UEMATSU T, Nakashima K, Harada TL, Nasu H, et al
    Artificial intelligence computer-aided detection enhances synthesized mammograms: comparison with original digital mammograms alone and in combination with tomosynthesis images in an experimental setting.
    Breast Cancer. 2023;30:46-55.
    PubMed     Abstract available

    December 2022
  79. ANUSZKIEWICZ K, Jankau J, Kur M
    What do we know about treating breast-cancer-related lymphedema? Review of the current knowledge about therapeutic options.
    Breast Cancer. 2022 Dec 26. doi: 10.1007/s12282-022-01428.
    PubMed     Abstract available

  80. TAJI T, Odan N, Kataoka Y, Ikeda M, et al
    Promoters of BRCA testing under insurance coverage for non-metastatic breast cancer patients in Japan: a retrospective cohort study.
    Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01424.
    PubMed     Abstract available

  81. TADA K, Kumamaru H, Miyata H, Asaga S, et al
    Characteristics of female breast cancer in japan: annual report of the National Clinical Database in 2018.
    Breast Cancer. 2022 Dec 22. doi: 10.1007/s12282-022-01423.
    PubMed     Abstract available

  82. MANFUKU M, Nishigami T, Mibu A, Yamashita H, et al
    Predictors of persistent post-surgical pain intensity and interference at 1 year after breast cancer surgery: assessing central sensitization, central sensitivity symptoms, and psychological factors.
    Breast Cancer. 2022 Dec 18. doi: 10.1007/s12282-022-01420.
    PubMed     Abstract available

  83. KAWAMOTO T, Shikama N, Imano N, Kubota H, et al
    Incidence of and risk factors for non-hematologic toxicity with combined radiotherapy and CDK4/6 inhibitors in metastatic breast cancer using dose-volume parameters analysis: a multicenter cohort study.
    Breast Cancer. 2022 Dec 17. doi: 10.1007/s12282-022-01422.
    PubMed     Abstract available

  84. CHU J, Min KW, Kim DH, Son BK, et al
    High PPFIA1 expression promotes cancer survival by suppressing CD8+ T cells in breast cancer: drug discovery and machine learning approach.
    Breast Cancer. 2022 Dec 7. doi: 10.1007/s12282-022-01419.
    PubMed     Abstract available

  85. WATZEK JT, Gordon LG, Sandler CX, Spence RR, et al
    A cost-consequences analysis of the SAFE trial: a comparative, effectiveness trial evaluating high- versus low-supervision of an exercise intervention for women with breast cancer.
    Breast Cancer. 2022 Dec 3. doi: 10.1007/s12282-022-01418.
    PubMed     Abstract available

    November 2022
  86. NGUYEN HM, Paulishak W, Oladejo M, Wood L, et al
    Dynamic tumor microenvironment, molecular heterogeneity, and distinct immunologic portrait of triple-negative breast cancer: an impact on classification and treatment approaches.
    Breast Cancer. 2022 Nov 18. pii: 10.1007/s12282-022-01415.
    PubMed     Abstract available

  87. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    Correction to: The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Nov 17. pii: 10.1007/s12282-022-01416.

  88. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    Conservative axillary surgery is emerging in the surgical management of breast cancer.
    Breast Cancer. 2022 Nov 7. pii: 10.1007/s12282-022-01409.
    PubMed     Abstract available

  89. SHIRAISHI M, Sowa Y, Tsuge I, Shiraishi A, et al
    Risk factors associated with chronic pain after mastectomy: a prospective study with a 5-year follow-up in Japan.
    Breast Cancer. 2022;29:1133-1139.
    PubMed     Abstract available

  90. KARAKAWA R, Konishi T, Yoshimatsu H, Fuse Y, et al
    Comparison of short-term outcomes between pedicled- and free-flap autologous breast reconstruction: a nationwide inpatient database study in Japan.
    Breast Cancer. 2022;29:1067-1075.
    PubMed     Abstract available

  91. ALAM B, Akbari AR, Alali B, Thankan E, et al
    Antibiotic prophylaxis in breast surgery: a meta-analysis to identify the optimal strategy to reduce infection rates in breast surgery.
    Breast Cancer. 2022;29:945-956.
    PubMed     Abstract available

  92. MUSTAFA ALI MK, Samhouri Y, Law JY, Khan C, et al
    Patterns of treatment and their outcomes in primary breast lymphoma; a comprehensive population-based analysis.
    Breast Cancer. 2022;29:1022-1031.
    PubMed     Abstract available

  93. HASHIMOTO R, Akashi-Tanaka S, Watanabe C, Masuda H, et al
    Diagnostic performance of dedicated breast positron emission tomography.
    Breast Cancer. 2022;29:1013-1021.
    PubMed     Abstract available

  94. BAILEY S, Ezratty C, Mhango G, Lin JJ, et al
    Clinical and sociodemographic risk factors associated with the development of second primary cancers among postmenopausal breast cancer survivors.
    Breast Cancer. 2022 Nov 1. pii: 10.1007/s12282-022-01411.
    PubMed     Abstract available

    October 2022
  95. SUZUKI K, Sasada S, Nishi H, Kimura Y, et al
    Impact of oral hygiene on febrile neutropenia during breast cancer chemotherapy.
    Breast Cancer. 2022 Oct 21. pii: 10.1007/s12282-022-01410.
    PubMed     Abstract available

  96. SEKIGUCHI K, Sumi M, Saito A, Zenda S, et al
    The effectiveness of moisturizer on acute radiation-induced dermatitis in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 Oct 18. pii: 10.1007/s12282-022-01403.
    PubMed     Abstract available

  97. MAVROPALIAS G, Cormie P, Peddle-McIntyre CJ, Galvao DA, et al
    The effects of home-based exercise therapy for breast cancer-related fatigue induced by radical radiotherapy.
    Breast Cancer. 2022 Oct 14. pii: 10.1007/s12282-022-01408.
    PubMed     Abstract available

    September 2022
  98. COLOMBAGE UN, Soh SE, Lin KY, Kruger J, et al
    The feasibility of pelvic floor training to treat urinary incontinence in women with breast cancer: a telehealth intervention trial.
    Breast Cancer. 2022 Sep 26. pii: 10.1007/s12282-022-01405.
    PubMed     Abstract available

  99. LIAO N, Li C, Cao L, Chen Y, et al
    Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node.
    Breast Cancer. 2022 Sep 21. pii: 10.1007/s12282-022-01400.
    PubMed     Abstract available

  100. YANG ZY, Yin SP, Ren Q, Lu DW, et al
    Correction to: BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
    Breast Cancer. 2022 Sep 16. pii: 10.1007/s12282-022-01402.

  101. MANSFIELD C, Botha W, Vondeling GT, Klein K, et al
    Patient preferences for features of HER2-targeted treatment of advanced or metastatic breast cancer: a discrete-choice experiment study.
    Breast Cancer. 2022 Sep 8. pii: 10.1007/s12282-022-01394.
    PubMed     Abstract available

  102. ALEIXO GFP, Valente SA, Wei W, Chen PH, et al
    Sarcopenia detected with bioelectrical impedance versus CT scan and chemotherapy tolerance in patients with early breast cancer.
    Breast Cancer. 2022 Sep 5. pii: 10.1007/s12282-022-01401.
    PubMed     Abstract available

  103. YAMAMOTO Y, Yamashiro H, Schneeweiss A, Muller V, et al
    Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational stu
    Breast Cancer. 2022 Sep 3. pii: 10.1007/s12282-022-01399.
    PubMed     Abstract available

  104. JUNG J, Hwang KT, Choi IS, Kim BH, et al
    Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database.
    Breast Cancer. 2022;29:889-898.
    PubMed     Abstract available

  105. UEMATSU T
    Sensitivity and specificity of screening mammography without clinical breast examination among Japanese women aged 40-49 years: analysis of data from the J-START results.
    Breast Cancer. 2022;29:928-931.
    PubMed     Abstract available

  106. WOO JW, Choi HY, Kim M, Chung YR, et al
    miR-145, miR-205 and miR-451: potential tumor suppressors involved in the progression of in situ to invasive carcinoma of the breast.
    Breast Cancer. 2022;29:814-824.
    PubMed     Abstract available

    August 2022
  107. NGAN TT, Browne S, Goodwin M, Van Minh H, et al
    Cost-effectiveness of clinical breast examination screening programme among HER2-positive breast cancer patients: a modelling study.
    Breast Cancer. 2022 Aug 26. pii: 10.1007/s12282-022-01398.
    PubMed     Abstract available

  108. CINAR V, Hamurcu Z, Guler A, Nurdinov N, et al
    Serotonin 5-HT7 receptor is a biomarker poor prognostic factor and induces proliferation of triple-negative breast cancer cells through FOXM1.
    Breast Cancer. 2022 Aug 25. pii: 10.1007/s12282-022-01391.
    PubMed     Abstract available

  109. KONISHI T, Tanabe M, Michihata N, Matsui H, et al
    Risk factors for arm lymphedema following breast cancer surgery: a Japanese nationwide database study of 84,022 patients.
    Breast Cancer. 2022 Aug 23. pii: 10.1007/s12282-022-01395.
    PubMed     Abstract available

  110. ZHU Y, Iwamoto T, Kajiwara Y, Takahashi Y, et al
    Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery.
    Breast Cancer. 2022 Aug 22. pii: 10.1007/s12282-022-01397.
    PubMed     Abstract available

  111. HAJI GHAFFARI M, Simonian M, Salimi A, Mirzadegan E, et al
    A novel ADC targeting cell surface fibromodulin in a mouse model of triple-negative breast cancer.
    Breast Cancer. 2022 Aug 18. pii: 10.1007/s12282-022-01393.
    PubMed     Abstract available

    July 2022
  112. KOTANI H, Masuda N, Yamashita T, Naito Y, et al
    Efficacy and safety of talazoparib in Japanese patients with germline BRCA-mutated locally advanced or metastatic breast cancer: results of the phase 1 dose-expansion study.
    Breast Cancer. 2022 Jul 30. pii: 10.1007/s12282-022-01390.
    PubMed     Abstract available

  113. ZHU J, Wu W, Togashi Y, Taira Nihira N, et al
    Alteration of Trop-2 expression in breast cancer cells by clinically used therapeutic agents and acquired tamoxifen resistance.
    Breast Cancer. 2022 Jul 27. pii: 10.1007/s12282-022-01389.
    PubMed     Abstract available

  114. MOTALEBZADEH J, Eskandari E
    Comprehensive analysis of DRAIC and TP53TG1 in breast cancer luminal subtypes through the construction of lncRNAs regulatory model.
    Breast Cancer. 2022 Jul 24. pii: 10.1007/s12282-022-01385.
    PubMed     Abstract available

  115. NOZAKI M, Kagami Y, Takahashi M, Machida R, et al
    Evaluation of breast cosmetic changes with a computer-software; the breast cancer conservative treatment cosmetic results (BCCT. core) in hypofractionated whole breast irradiation after breast-conserving surgery-supplementary analysis of multicenter s
    Breast Cancer. 2022 Jul 21. pii: 10.1007/s12282-022-01384.
    PubMed     Abstract available

  116. WOOD KC, Hidde M, Kendig T, Pergolotti M, et al
    Community-based outpatient rehabilitation for the treatment of breast cancer-related upper extremity disability: an evaluation of practice-based evidence.
    Breast Cancer. 2022 Jul 21. pii: 10.1007/s12282-022-01388.
    PubMed     Abstract available

  117. NAMBA T, Matsuda N, Rahman M, Kanomata N, et al
    Association between mammographic breast composition and breast cancer risk among Japanese women: a retrospective cohort study.
    Breast Cancer. 2022 Jul 13. pii: 10.1007/s12282-022-01376.
    PubMed     Abstract available

  118. NOURI-MAJD S, Salari-Moghaddam A, Benisi-Kohansal S, Azadbakht L, et al
    Dietary intake of branched-chain amino acids in relation to the risk of breast cancer.
    Breast Cancer. 2022 Jul 6. pii: 10.1007/s12282-022-01379.
    PubMed     Abstract available

  119. HAN R, Yang H, Ling C, Lu L, et al
    Neurospora crassa is a potential source of anti-cancer agents against breast cancer.
    Breast Cancer. 2022 Jul 5. pii: 10.1007/s12282-022-01383.
    PubMed     Abstract available

  120. TSUDA H, Kurosumi M, Akiyama F, Ohno S, et al
    Validation of a nuclear grading system for resected stage I-IIIA, high-risk, node-negative invasive breast carcinoma in the N.SAS-BC 01 trial.
    Breast Cancer. 2022;29:720-729.
    PubMed     Abstract available

  121. YOSHIDA K, Nose T, Otani Y, Asahi S, et al
    A Japanese prospective multi-institutional feasibility study on accelerated partial breast irradiation using multicatheter interstitial brachytherapy: clinical results with a median follow-up of 60 months.
    Breast Cancer. 2022;29:636-644.
    PubMed     Abstract available

  122. NAKAYAMA S, Masuda H, Miura S, Kuwayama T, et al
    Identifying ductal carcinoma in situ cases not requiring surgery to exclude postoperative upgrade to invasive ductal carcinoma.
    Breast Cancer. 2022;29:610-617.
    PubMed     Abstract available

  123. HAYASHI S, Kubo M, Kaneshiro K, Kai M, et al
    Genetic medicine is accelerating in Japan.
    Breast Cancer. 2022;29:659-665.
    PubMed     Abstract available

  124. GANDOMKAR Z, Lewis SJ, Li T, Ekpo EU, et al
    A machine learning model based on readers' characteristics to predict their performances in reading screening mammograms.
    Breast Cancer. 2022;29:589-598.
    PubMed     Abstract available

    June 2022
  125. DANG LA, Chazard E, Poncelet E, Serb T, et al
    Impact of artificial intelligence in breast cancer screening with mammography.
    Breast Cancer. 2022 Jun 28. pii: 10.1007/s12282-022-01375.
    PubMed     Abstract available

  126. WAGONER CW, Lee JT, Hanson ED, Kerr ZY, et al
    Impact of community-based exercise on fatigue in early breast cancer survivors: identifying potential determinants of change.
    Breast Cancer. 2022 Jun 24. pii: 10.1007/s12282-022-01380.
    PubMed     Abstract available

  127. WANG W, Qiu P, Li J
    Internal mammary lymph node metastasis in breast cancer patients based on anatomical imaging and functional imaging.
    Breast Cancer. 2022 Jun 24. pii: 10.1007/s12282-022-01377.
    PubMed     Abstract available

  128. SHIMOMURA A, Nagahashi M, Kumamaru H, Aogi K, et al
    Clinicopathological features of male patients with breast cancer based on a nationwide registry database in Japan.
    Breast Cancer. 2022 Jun 22. pii: 10.1007/s12282-022-01378.
    PubMed     Abstract available

  129. CHEN M, Chen W, Liu D, Chen W, et al
    Prognostic values of clinical and molecular features in HER2 low-breast cancer with hormonal receptor overexpression: features of HER2-low breast cancer.
    Breast Cancer. 2022 Jun 21. pii: 10.1007/s12282-022-01364.
    PubMed     Abstract available

  130. ZHANG X, Zhao X, Chang L, Liu F, et al
    LncRNA FOXD3-AS1 promotes breast cancer progression by mediating ARF6.
    Breast Cancer. 2022 Jun 9. pii: 10.1007/s12282-022-01373.
    PubMed     Abstract available

  131. LI Q, Lesseur C, Neugut AI, Santella RM, et al
    The associations of healthy lifestyle index with breast cancer incidence and mortality in a population-based study.
    Breast Cancer. 2022 Jun 3. pii: 10.1007/s12282-022-01374.
    PubMed     Abstract available

  132. VAZEH H, Behboudi E, Hashemzadeh-Omran A, Moradi A, et al
    Live-attenuated poliovirus-induced extrinsic apoptosis through Caspase 8 within breast cancer cell lines expressing CD155.
    Breast Cancer. 2022 Jun 1. pii: 10.1007/s12282-022-01372.
    PubMed     Abstract available

    May 2022
  133. MINOURA Y, Takahashi M, Maeda H, Kuwahara S, et al
    Significance of prostate/pancreatic/skin cancer family history for detecting BRCA2 pathogenic variant careers among patients with breast cancer.
    Breast Cancer. 2022 May 31. pii: 10.1007/s12282-022-01360.
    PubMed     Abstract available

  134. KATAOKA A, Ueno T, Yamauchi H, Uehiro N, et al
    Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC).
    Breast Cancer. 2022 May 23. pii: 10.1007/s12282-022-01362.
    PubMed     Abstract available

  135. LIN SQ, Su CM, Wu HC, Chou YY, et al
    Effect of patient decision aids on decisional conflict and regret associated with breast cancer surgery: a randomized controlled trial.
    Breast Cancer. 2022 May 19. pii: 10.1007/s12282-022-01370.
    PubMed     Abstract available

  136. BAN K, Tsunoda H, Togashi S, Kawakami M, et al
    Comparative study of the usefulness of adjunctive tomosynthesis in breast cancer screening by mammography and ultrasound in Japan.
    Breast Cancer. 2022 May 18. pii: 10.1007/s12282-022-01358.
    PubMed     Abstract available

  137. KHODABANDEH Z, Valilo M, Velaei K, Pirpour Tazehkand A, et al
    The potential role of nicotine in breast cancer initiation, development, angiogenesis, invasion, metastasis, and resistance to therapy.
    Breast Cancer. 2022 May 18. pii: 10.1007/s12282-022-01369.
    PubMed     Abstract available

  138. PANG Y, Wei Y, Kartsonaki C
    Associations of adiposity and weight change with recurrence and survival in breast cancer patients: a systematic review and meta-analysis.
    Breast Cancer. 2022 May 17. pii: 10.1007/s12282-022-01355.
    PubMed     Abstract available

  139. ROY P, Sur S, Das S, Wui WT, et al
    Phytochemical-conjugated bio-safe gold nanoparticles in breast cancer: a comprehensive update.
    Breast Cancer. 2022 May 16. pii: 10.1007/s12282-022-01368.
    PubMed     Abstract available

  140. PARK JK, Seo J, Yang EJ, Kang Y, et al
    Association of lymphatic flow velocity with surgical outcomes in patients undergoing lymphovenous anastomosis for breast cancer-related lymphedema.
    Breast Cancer. 2022 May 12. pii: 10.1007/s12282-022-01363.
    PubMed     Abstract available

  141. LI X, Wang Y, Zhang Y, Liu B, et al
    Overexpression of MCAM induced by SMYD2-H3K36me2 in breast cancer stem cell properties.
    Breast Cancer. 2022 May 12. pii: 10.1007/s12282-022-01365.
    PubMed     Abstract available

  142. HO PJ, Khng AJ, Tan BK, Tan EY, et al
    Relevance of the MHC region for breast cancer susceptibility in Asians.
    Breast Cancer. 2022 May 11. pii: 10.1007/s12282-022-01366.
    PubMed     Abstract available

  143. RUIDAS B, Sur TK, Das Mukhopadhyay C, Sinha K, et al
    Quercetin: a silent retarder of fatty acid oxidation in breast cancer metastasis through steering of mitochondrial CPT1.
    Breast Cancer. 2022 May 5. pii: 10.1007/s12282-022-01356.
    PubMed     Abstract available

  144. NARA M, Ishihara S, Kitano A, Tamura N, et al
    Does breast-conserving surgery with radiotherapy in BRCA-mutation carriers significantly increase ipsilateral breast tumor recurrence? A systematic review and meta-analysis.
    Breast Cancer. 2022;29:394-401.
    PubMed     Abstract available

  145. HIRATA M, Toda H, Higo N, Shinden Y, et al
    Modification of oncoplastic breast surgery with immediate volume replacement using a thoracodorsal adipofascial flap.
    Breast Cancer. 2022;29:531-540.
    PubMed     Abstract available

  146. NASIF D, Real S, Roque M, Branham MT, et al
    CDC42 as an epigenetic regulator of ID4 in triple-negative breast tumors.
    Breast Cancer. 2022;29:562-573.
    PubMed     Abstract available

  147. GRUNTKEMEIER L, Khurana A, Bischoff FZ, Hoffmann O, et al
    Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray-HER2-FISH workflow.
    Breast Cancer. 2022;29:487-497.
    PubMed     Abstract available

  148. GAO P, Wang X, Bai P, Kong X, et al
    Clinical outcomes and patient satisfaction with the use of biological and synthetic meshes in one-stage implant-based breast reconstruction.
    Breast Cancer. 2022;29:450-457.
    PubMed     Abstract available

    April 2022
  149. MONSIVAIS P, Amiri S, Robison J, Pflugeisen C, et al
    Correction to: Racial and socioeconomic inequities in breast cancer screening before and during the COVID-19 pandemic: analysis of two cohorts of women 50 years + .
    Breast Cancer. 2022 Apr 30. pii: 10.1007/s12282-022-01361.

  150. KIKAWA Y, Kotake T, Tsuyuki S, Kang Y, et al
    Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC study.
    Breast Cancer. 2022 Apr 23. pii: 10.1007/s12282-022-01357.
    PubMed     Abstract available

  151. BLATNIK A, Ribnikar D, Setrajcic Dragos V, Novakovic S, et al
    BAP1-defficient breast cancer in a patient with BAP1 cancer syndrome.
    Breast Cancer. 2022 Apr 5. pii: 10.1007/s12282-022-01354.
    PubMed     Abstract available

  152. MONSIVAIS P, Amiri S, Robison J, Pflugeisen C, et al
    Racial and socioeconomic inequities in breast cancer screening before and during the COVID-19 pandemic: analysis of two cohorts of women 50 years + .
    Breast Cancer. 2022 Apr 2. pii: 10.1007/s12282-022-01352.
    PubMed     Abstract available

    March 2022
  153. HENG YJ, Love S, DeHart JC, Fingeroth JD, et al
    The association of infectious mononucleosis and invasive breast cancer in The Health of Women (HOW) Study((R)).
    Breast Cancer. 2022 Mar 26. pii: 10.1007/s12282-022-01351.
    PubMed     Abstract available

  154. TERADA M, Miyashita M, Kumamaru H, Miyata H, et al
    Surgical treatment trends and identification of primary breast tumors after surgery in occult breast cancer: a study based on the Japanese National Clinical Database-Breast Cancer Registry.
    Breast Cancer. 2022 Mar 22. pii: 10.1007/s12282-022-01348.
    PubMed     Abstract available

  155. PINTO CS, Peleteiro B, Pinto CA, Osorio F, et al
    Initial experience with targeted axillary dissection after neoadjuvant therapy in breast cancer patients.
    Breast Cancer. 2022 Mar 19. pii: 10.1007/s12282-022-01349.
    PubMed     Abstract available

  156. FICARRA S, Thomas E, Bianco A, Gentile A, et al
    Impact of exercise interventions on physical fitness in breast cancer patients and survivors: a systematic review.
    Breast Cancer. 2022 Mar 12. pii: 10.1007/s12282-022-01347.
    PubMed     Abstract available

  157. JUNJUN S, Yangyanqiu W, Jing Z, Jie P, et al
    Prognostic model based on six PD-1 expression and immune infiltration-associated genes predicts survival in breast cancer.
    Breast Cancer. 2022 Mar 1. pii: 10.1007/s12282-022-01344.
    PubMed     Abstract available

  158. JAMSHIDI F, Farzad M, MacDermid JC, Varahra A, et al
    Assessing the content based on ICF and quality based on COSMIN criteria of patient-reported outcome measures of functioning in breast cancer survivors: a systematic review.
    Breast Cancer. 2022 Mar 1. pii: 10.1007/s12282-022-01340.
    PubMed     Abstract available

  159. OKAZAKI M, Muguruma M, Komiya T, Miyahara K, et al
    Beneficial effects of transdermal administration of tamoxifen on capsular contracture after breast implantation in murine models.
    Breast Cancer. 2022;29:343-351.
    PubMed     Abstract available

  160. ZELLINGER B, Bodenhofer U, Englander IA, Kronberger C, et al
    Hsa-miR-3651 could serve as a novel predictor for in-breast recurrence via FRMD3.
    Breast Cancer. 2022;29:274-286.
    PubMed     Abstract available

  161. BERNINI M, Meattini I, Saieva C, Becherini C, et al
    Pre-pectoral breast reconstruction: early and long-term safety evaluation of 146 unselected cases of the early pre-pectoral era of a single-institution, including cases with previous breast irradiation and post-mastectomy radiation therapy.
    Breast Cancer. 2022;29:302-313.
    PubMed     Abstract available

  162. FAULKNER HR, Coopey SB, Liao EC, Specht M, et al
    The safety of performing breast reconstruction during the COVID-19 pandemic.
    Breast Cancer. 2022;29:242-246.
    PubMed     Abstract available

    February 2022
  163. YUEN S, Monzawa S, Gose A, Yanai S, et al
    Impact of background parenchymal enhancement levels on the diagnosis of contrast-enhanced digital mammography in evaluations of breast cancer: comparison with contrast-enhanced breast MRI.
    Breast Cancer. 2022 Feb 26. pii: 10.1007/s12282-022-01345.
    PubMed     Abstract available

  164. KONISHI T, Fujiogi M, Michihata N, Kumazawa R, et al
    Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan.
    Breast Cancer. 2022 Feb 26. pii: 10.1007/s12282-022-01346.
    PubMed     Abstract available

  165. LEINERT E, Schwentner L, Janni W, Wockel A, et al
    Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy-results from the prospective multi-center BRENDA II study.
    Breast Cancer. 2022 Feb 18. pii: 10.1007/s12282-021-01321.
    PubMed     Abstract available

  166. YUAN B, Liu W, Huo M, Zhang J, et al
    The hub ten gene-based risk score system using RNA m(6)A methylation regulator features and tumor immune microenvironment in breast cancer.
    Breast Cancer. 2022 Feb 16. pii: 10.1007/s12282-022-01341.
    PubMed     Abstract available

  167. LOPEZ C, Bosch R, Korzynska A, Garcia-Rojo M, et al
    CD68 and CD83 immune populations in non-metastatic axillary lymph nodes are of prognostic value for the survival and relapse of breast cancer patients.
    Breast Cancer. 2022 Feb 8. pii: 10.1007/s12282-022-01336.
    PubMed     Abstract available

  168. DIEHM YF, Marstaller K, Seckler AM, Berger MR, et al
    The collagenase of the bacterium Clostridium histolyticum does not favor metastasis of breast cancer.
    Breast Cancer. 2022 Feb 7. pii: 10.1007/s12282-022-01337.
    PubMed     Abstract available

    January 2022
  169. ZAREIE B, Rasouli MA, Poorolajal J
    Risk of primary lung cancer after breast cancer radiotherapy: a systematic review and meta-analysis.
    Breast Cancer. 2022 Jan 28. pii: 10.1007/s12282-021-01318.
    PubMed     Abstract available

  170. DASHTI F, Soltani S, Benisi-Kohansal S, Azadbakht L, et al
    Consumption of dairy products and odds of breast cancer: an Iranian case-control study.
    Breast Cancer. 2022 Jan 27. pii: 10.1007/s12282-021-01317.
    PubMed     Abstract available

  171. YANG A, Wu M, Ni M, Zhang L, et al
    A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer.
    Breast Cancer. 2022 Jan 21. pii: 10.1007/s12282-021-01326.
    PubMed     Abstract available

  172. YANG ZY, Yin SP, Ren Q, Lu DW, et al
    BAHD1 serves as a critical regulator of breast cancer cell proliferation and invasion.
    Breast Cancer. 2022 Jan 19. pii: 10.1007/s12282-022-01333.
    PubMed     Abstract available

  173. ZENG Q, Lin X, Chen H, Yan Y, et al
    Multi-time scale transcriptomic analysis on the dynamic process of tamoxifen resistance development in breast cancer cell lines.
    Breast Cancer. 2022 Jan 18. pii: 10.1007/s12282-021-01325.
    PubMed     Abstract available

  174. GU JH, He C, Zhao QY, Jiang TA, et al
    Usefulness of new shear wave elastography in early predicting the efficacy of neoadjuvant chemotherapy for patients with breast cancer: where and when to measure is optimal?
    Breast Cancer. 2022 Jan 17. pii: 10.1007/s12282-021-01327.
    PubMed     Abstract available

  175. MORITA M, Shimomura A, Tokuda E, Horimoto Y, et al
    Is adjuvant chemotherapy necessary in older patients with breast cancer?
    Breast Cancer. 2022 Jan 15. pii: 10.1007/s12282-021-01329.
    PubMed     Abstract available

  176. CARRETTI G, Mirandola D, Maestrini F, Sequi L, et al
    Quality of life improvement in breast cancer survivors affected by upper limb lymphedema through a novel multiperspective physical activity methodology: a monocentric pilot study.
    Breast Cancer. 2022 Jan 13. pii: 10.1007/s12282-021-01322.
    PubMed     Abstract available

  177. UDDIN MN, Wang X
    Identification of key tumor stroma-associated transcriptional signatures correlated with survival prognosis and tumor progression in breast cancer.
    Breast Cancer. 2022 Jan 12. pii: 10.1007/s12282-022-01332.
    PubMed     Abstract available

  178. ABDELRAZEK MA, Nageb A, Barakat LA, Abouzid A, et al
    BC-DETECT: combined detection of serum HE4 and TFF3 improves breast cancer diagnostic efficacy.
    Breast Cancer. 2022 Jan 7. pii: 10.1007/s12282-021-01328.
    PubMed     Abstract available

  179. HAILEY V, Rojas-Garcia A, Kassianos AP
    A systematic review of behaviour change techniques used in interventions to increase physical activity among breast cancer survivors.
    Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01323.
    PubMed     Abstract available

  180. NIMBI FM, Magno S, Agostini L, Di Micco A, et al
    Sexuality in breast cancer survivors: sexual experiences, emotions, and cognitions in a group of women under hormonal therapy.
    Breast Cancer. 2022 Jan 6. pii: 10.1007/s12282-021-01320.
    PubMed     Abstract available

  181. SUETA A, Yamamoto-Ibusuki M, Tomiguchi M, Fujiki Y, et al
    Predictive and prognostic significance of BRCAness in HER2-negative breast cancer.
    Breast Cancer. 2022 Jan 5. pii: 10.1007/s12282-021-01319.
    PubMed     Abstract available

    November 2021
  182. SU SY
    Nationwide mammographic screening and breast cancer mortality in Taiwan: an interrupted time-series analysis.
    Breast Cancer. 2021 Nov 26. pii: 10.1007/s12282-021-01315.
    PubMed     Abstract available

  183. MUKAND NH, Ko NY, Nabulsi NA, Hubbard CC, et al
    The association between physical health-related quality of life, physical functioning, and risk of contralateral breast cancer among older women.
    Breast Cancer. 2021 Nov 19. pii: 10.1007/s12282-021-01309.
    PubMed     Abstract available

  184. EVANS A, Sim YT, Lawson B, Macaskill J, et al
    The value of prognostic ultrasound features of breast cancer in different molecular subtypes with a focus on triple negative disease.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01311.
    PubMed     Abstract available

  185. VAN EGDOM LSE, de Ligt KM, de Munck L, Koppert LB, et al
    Predictors of delayed breast reconstruction in the Netherlands: a 5-year follow-up study in stage I-III breast cancer patients.
    Breast Cancer. 2021 Nov 15. pii: 10.1007/s12282-021-01313.
    PubMed     Abstract available

  186. WANG C, Lin Y, Zhu H, Zhou Y, et al
    Breast-conserving therapy for breast cancer with BRCA mutations: a meta-analysis.
    Breast Cancer. 2021 Nov 11. pii: 10.1007/s12282-021-01312.
    PubMed     Abstract available

  187. MAROUFI NF, Rashidi M, Vahedian V, Jahanbazi R, et al
    Effect of Apatinib plus melatonin on vasculogenic mimicry formation by cancer stem cells from breast cancer cell line.
    Breast Cancer. 2021 Nov 1. pii: 10.1007/s12282-021-01310.
    PubMed     Abstract available

  188. LI X, Lin M, Xu J, Pang Y, et al
    New variant of breast-invasive lobular carcinoma with solid and encapsulated papillary carcinoma growth pattern.
    Breast Cancer. 2021;28:1383-1388.
    PubMed     Abstract available

  189. KOTOULA V, Papadopoulou K, Tikas I, Fostira F, et al
    Follow-up of tissue genomics in BRCA1/2 carriers who underwent prophylactic surgeries.
    Breast Cancer. 2021;28:1367-1382.
    PubMed     Abstract available

  190. TANG X, Nakanishi Y, Kobayashi H, Nishimaki H, et al
    Mixed ductal-lobular carcinoma: an analysis of CDH1 DNA copy number variation and mutation.
    Breast Cancer. 2021;28:1318-1327.
    PubMed     Abstract available

  191. SIEGWART LC, Fischer S, Diehm YF, Heil JM, et al
    The transverse musculocutaneous gracilis flap for autologous breast reconstruction: focus on donor site morbidity.
    Breast Cancer. 2021;28:1273-1282.
    PubMed     Abstract available

  192. YOSHIDA R
    Hereditary breast and ovarian cancer (HBOC): review of its molecular characteristics, screening, treatment, and prognosis.
    Breast Cancer. 2021;28:1167-1180.
    PubMed     Abstract available

  193. TAKAHAMA N, Tozaki M, Ohgiya Y
    Current status of MRI-guided vacuum-assisted breast biopsy in Japan.
    Breast Cancer. 2021;28:1188-1194.
    PubMed     Abstract available

  194. TOZAKI M, Nakamura S
    Current status of breast cancer screening in high-risk women in Japan.
    Breast Cancer. 2021;28:1181-1187.
    PubMed     Abstract available

    October 2021
  195. VEGUNTA S, Bhatt AA, Choudhery SA, Pruthi S, et al
    Identifying women with increased risk of breast cancer and implementing risk-reducing strategies and supplemental imaging.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01298.
    PubMed     Abstract available

  196. YOTSUMOTO D, Sagara Y, Kumamaru H, Niikura N, et al
    Trends in adjuvant therapy after breast-conserving surgery for ductal carcinoma in situ of breast: a retrospective cohort study using the National Breast Cancer Registry of Japan.
    Breast Cancer. 2021 Oct 19. pii: 10.1007/s12282-021-01307.
    PubMed     Abstract available

  197. TAKAHASHI M, Tokunaga E, Mori J, Tanizawa Y, et al
    Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer.
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01295.
    PubMed     Abstract available

  198. ROBERTS S, Rojas A, DiRaimo G, Orlando M, et al
    Defer surgery in operable breast cancer: how long is too long?
    Breast Cancer. 2021 Oct 18. pii: 10.1007/s12282-021-01302.
    PubMed     Abstract available

  199. DIAZ-ROLDAN J, Eguia-Larrea M, Rubio-Sanchez T, Munoz-Bellvis L, et al
    Systematic review of synchronous contralateral axillary metastases in breast cancer: really M1 disease?
    Breast Cancer. 2021 Oct 15. pii: 10.1007/s12282-021-01293.
    PubMed     Abstract available

  200. OZAKI A, Tachibana K, Ohtake T
    Correction to: Challenges and future directions in breast cancer care in Fukushima prefecture in Japan: correspondence to "A survey on the current status of clinical resources for diagnosis and treatment of breast cancer in rural hospitals of the Toho
    Breast Cancer. 2021 Oct 13. pii: 10.1007/s12282-021-01306.

  201. LI B, Cheng X, Zhu Y, Wan H, et al
    FOXA1 of regulatory variant associated with risk of breast cancer through allele-specific enhancer in the Chinese population.
    Breast Cancer. 2021 Oct 11. pii: 10.1007/s12282-021-01305.
    PubMed     Abstract available

  202. LEBOK P, Bonte H, Kluth M, Moller-Koop C, et al
    6q deletion is frequent but unrelated to patient prognosis in breast cancer.
    Breast Cancer. 2021 Oct 8. pii: 10.1007/s12282-021-01301.
    PubMed     Abstract available

  203. HORISAWA N, Adachi Y, Takatsuka D, Nozawa K, et al
    The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status.
    Breast Cancer. 2021 Oct 7. pii: 10.1007/s12282-021-01303.
    PubMed     Abstract available

    September 2021
  204. NOGUCHI M, Inokuchi M, Yokoi-Noguchi M, Morioka E, et al
    The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Breast Cancer. 2021 Sep 30. pii: 10.1007/s12282-021-01300.
    PubMed     Abstract available

  205. TAIRA N, Kashiwabara K, Tsurutani J, Kitada M, et al
    Correction to: Quality of life in a randomized phase II study to determine the optimal dose of 3-week cycle nab-paclitaxel in patients with metastatic breast cancer.
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01296.

  206. KOH SJ, Ohsumi S, Takahashi M, Fukuma E, et al
    Correction to: Prevalence of mutations in BRCA and homologous recombination repair genes and real-world standard of care of Asian patients with HER2-negative metastatic breast cancer starting first-line systemic cytotoxic chemotherapy: subgroup analys
    Breast Cancer. 2021 Sep 25. pii: 10.1007/s12282-021-01299.

  207. MORI N, Abe H, Mugikura S, Miyashita M, et al
    Discriminating low-grade ductal carcinoma in situ (DCIS) from non-low-grade DCIS or DCIS upgraded to invasive carcinoma: effective texture features on ultrafast dynamic contrast-enhanced magnetic resonance imaging.
    Breast Cancer. 2021;28:1141-1153.
    PubMed     Abstract available

  208. NAKASHIMA K, Uematsu T, Harada TL, Takahashi K, et al
    Can breast MRI and adjunctive Doppler ultrasound improve the accuracy of predicting pathological complete response after neoadjuvant chemotherapy?
    Breast Cancer. 2021;28:1120-1130.
    PubMed     Abstract available

    July 2021
  209. MINEMURA H, Takagi K, Sato A, Yamaguchi M, et al
    Isoforms of IDH in breast carcinoma: IDH2 as a potent prognostic factor associated with proliferation in estrogen-receptor positive cases.
    Breast Cancer. 2021;28:915-926.
    PubMed     Abstract available

  210. TOZAKI M, Yabuuchi H, Goto M, Sasaki M, et al
    Effects of gadobutrol on background parenchymal enhancement and differential diagnosis between benign and malignant lesions in dynamic magnetic resonance imaging of the breast.
    Breast Cancer. 2021;28:927-936.
    PubMed     Abstract available

  211. TENG X, Hayashida T, Murata T, Nagayama A, et al
    A transposon screen identifies enhancement of NF-kappaB pathway as a mechanism of resistance to eribulin.
    Breast Cancer. 2021;28:884-895.
    PubMed     Abstract available

  212. TANAKA K, Masuda N, Hayashi N, Sagara Y, et al
    Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.
    Breast Cancer. 2021;28:896-903.
    PubMed     Abstract available

  213. XU C, Gu Z, Liu J, Lin X, et al
    Adenosquamous carcinoma of the breast: a population-based study.
    Breast Cancer. 2021;28:848-858.
    PubMed     Abstract available

    May 2021
  214. MEHRAJ U, Qayoom H, Mir MA
    Prognostic significance and targeting tumor-associated macrophages in cancer: new insights and future perspectives.
    Breast Cancer. 2021;28:539-555.
    PubMed     Abstract available

  215. AKASHI M, Yamaguchi R, Kusano H, Yamaguchi M, et al
    ER staining levels affect HER2 staining and heterogeneity.
    Breast Cancer. 2021;28:720-726.
    PubMed     Abstract available

  216. ZHANG R, Gao P, Han Y, Zhang R, et al
    Reliable assessment of BRCA1 and BRCA2 germline variants by next-generation sequencing: a multicenter study.
    Breast Cancer. 2021;28:672-683.
    PubMed     Abstract available

  217. JIA M, Liao N, Chen B, Zhang G, et al
    PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing.
    Breast Cancer. 2021;28:644-652.
    PubMed     Abstract available

    March 2021
  218. MCMULLEN ER, Skala SL, Gonzalez ME, Djomehri S, et al
    Subcellular localization of EZH2 phosphorylated at T367 stratifies metaplastic breast carcinoma subtypes.
    Breast Cancer. 2021;28:496-505.
    PubMed     Abstract available

  219. MAEDA H, Hayashida T, Watanuki R, Kikuchi M, et al
    Predictors of invasive disease in patients preoperatively diagnosed with ductal carcinoma without stromal invasion, with breast magnetic resonance imaging (MRI) and ultrasound (US).
    Breast Cancer. 2021;28:398-404.
    PubMed     Abstract available

  220. CORADINI D, Gambazza S, Oriana S, Ambrogi F, et al
    Gene expression profile of normal breast tissue and body mass index.
    Breast Cancer. 2021;28:488-495.
    PubMed     Abstract available

  221. FILIPE MD, Simons JM, Moeliker L, Waaijer L, et al
    Patient-reported outcomes of ductoscopy procedures for pathologic nipple discharge.
    Breast Cancer. 2021;28:471-477.
    PubMed     Abstract available

  222. VERDE F, Vigliar E, Romeo V, Campanino MR, et al
    Breast implant associated anaplastic large cell lymphoma (BIA-ALCL): a challenging cytological diagnosis with hybrid PET/MRI staging and follow-up.
    Breast Cancer. 2021;28:527-532.
    PubMed     Abstract available

  223. KUMARI K, Kumar S, Parida DK, Mishra SK, et al
    EZH2 knockdown in tamoxifen-resistant MCF-7 cells unravels novel targets for regaining sensitivity towards tamoxifen.
    Breast Cancer. 2021;28:355-367.
    PubMed     Abstract available

  224. GLASGOW A, Sechrist H, Bomeisl P, Gilmore H, et al
    Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review.
    Breast Cancer. 2021;28:321-328.
    PubMed     Abstract available

  225. CARRARA GFA, Evangelista AF, Scapulatempo-Neto C, Abrahao-Machado LF, et al
    Analysis of RPL37A, MTSS1, and HTRA1 expression as potential markers for pathologic complete response and survival.
    Breast Cancer. 2021;28:307-320.
    PubMed     Abstract available

  226. ZHAO JM, An Q, Sun CN, Li YB, et al
    Prognostic factors for breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes and the role of postmastectomy radiotherapy in these patients.
    Breast Cancer. 2021;28:298-306.
    PubMed     Abstract available

  227. VUKSANOVIC D, Sanmugarajah J, Lunn D, Sawhney R, et al
    Unmet needs in breast cancer survivors are common, and multidisciplinary care is underutilised: the Survivorship Needs Assessment Project.
    Breast Cancer. 2021;28:289-297.
    PubMed     Abstract available

  228. ALATAWI Y, Hansen RA, Chou C, Qian J, et al
    The impact of cognitive impairment on survival and medication adherence among older women with breast cancer.
    Breast Cancer. 2021;28:277-288.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.